Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H18ClNO2.ClH |
| Molecular Weight | 292.201 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@@H]1NC(C)(C)CO[C@@]1(O)C2=CC=CC(Cl)=C2
InChI
InChIKey=ORXTVTDGPVINDN-BTJVGWIPSA-N
InChI=1S/C13H18ClNO2.ClH/c1-9-13(16,17-8-12(2,3)15-9)10-5-4-6-11(14)7-10;/h4-7,9,15-16H,8H2,1-3H3;1H/t9-,13+;/m0./s1
| Molecular Formula | C13H18ClNO2 |
| Molecular Weight | 255.741 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Radafaxine (GW353162, ( )-(2S,3S)-2-(3-chlorophenyl-3,5,5-trimethyl-2-morphinol) or S,S-hydroxybupropion) is an active metabolite of bupropion. It acts as an inhibitor of the dopamine transporter. Radafaxine was investigated for the treatment of depression however, development was discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes. | 2009-05-15 |
|
| [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. | 2007-10-19 |
|
| Obesity drugs in clinical development. | 2006-04 |
|
| The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. | 2005-03-15 |
|
| Validated assays for human cytochrome P450 activities. | 2004-06 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00057213
Once-daily oral radafaxine (GW353162) (20-40-60mg) was investigated over an eight-week treatment period in phase 2 study in subjects with major depressive disorder
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:11:09 GMT 2025
by
admin
on
Mon Mar 31 18:11:09 GMT 2025
|
| Record UNII |
SYD411HZ3S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB29224
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
PRIMARY | |||
|
PP-54
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
PRIMARY | |||
|
SYD411HZ3S
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
PRIMARY | |||
|
CHEMBL1172928
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
PRIMARY | |||
|
C78023
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
PRIMARY | |||
|
DBSALT002075
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
PRIMARY | |||
|
DTXSID90909896
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
PRIMARY | |||
|
106083-71-0
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
PRIMARY | |||
|
100000092737
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
PRIMARY | |||
|
9838996
Created by
admin on Mon Mar 31 18:11:09 GMT 2025 , Edited by admin on Mon Mar 31 18:11:09 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|